Background. Osteoprotegerin (OPG), sclerostin and DKK1 constitute opposite bone turnover inhibitors, OPG inhibiting osteoclastogenesis while sclerostin and DKK1 exerting their inhibitory effects on osteoblastogenesis. Both proteins have been recognized as strong risk factors of vascular calcifications in non-dialysis chronic kidney disease (ND-CKD) patients. The aim of this study was to investigate the relationships between these inhibitors and coronary artery calcifications (CAC) in this population. Methods. A total of 241 ND-CKD patients [143 males; 69.0 (25.0-95.0) years; median estimated glomerular filtration rate using CKD-EPI 35.1 (6.7-120.1) mL/min/1.73 m 2 ] were enrolled in this cross-sectional study. All underwent chest multidetector computed tomography for CAC scoring. OPG, sclerostin, DKK1 and mineral metabolism markers including PTH and bone alkaline phosphatase were measured. Logistic regression analyses were used to study the relationships between CAC and these markers. Results. Decline in renal function was associated with a significant increase in OPG and sclerostin while a slight but significant decrease in DKK1 was observed. The main crude associations with presence of CAC were a high level of OPG [OR = 2.55 95% confidence interval (95% CI) (1.35-4.82) for a level ranging from 6.26 to 9.15 pmol/L and OR = 5.74 95% CI (2.87-11.5) for a level ≥9.15 pmol/L; P < 0.0001] and a high level of sclerostin [OR = 2.64 95% CI (1.39-5.00) for a level ranging from 0.748 to 1.139 ng/mL and OR = 3.78 95%
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I N T R O D U C T I O N
Vascular calcifications (VCs) are recognized as a strong predictor of all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients [1] [2] [3] . Presence of VC has been associated with numerous traditional risk factors including aging, hypertension and diabetes as well as with non-traditional risk factors including mineral metabolism disorders. Particular attention has also been devoted to the so-called adynamic bone disease, well described as an attenuated osteoclastic and osteoblastic activity and other features of low turnover bone which may also include low serum parathyroid hormone (PTH). Indeed, adynamic bone disease is reported to develop more frequently among CKD patients, probably due to parathyroidectomy or pharmacological PTH suppression, and constitutes a high risk factor for VC [4, 5] . The well-described bone-vascular axis in CKD, addressing the complex interactions between bone and vessel which share similar underlying mechanisms, let bone turnover inhibitors emerge as potential risk factors for VC. For example, osteoprotegerin (OPG), a bone-regulating protein belonging to the TNF receptor superfamily which regulates important aspects of osteoclast/osteoblast formation [6] is strongly associated with VC in CKD patients even though its actions in the vasculature and heart is still unclear [7, 8] . More recently, attention has focused on sclerostin and Dickkopf-1 (DKK1), novel candidates for this bone-vascular axis in CKD patients, which inhibit the Wnt canonical signalling pathway involved in bone formation by regulating osteoblast proliferation and differentiation [9] . Reports indicate discrepant association between DKK1 and sclerostin with VC: DKK1 is inversely associated to aortic calcifications [10] whereas a positive association is observed between sclerostin and aortic calcifications, in post-menopausal women [10] or diabetes mellitus [11] . Expression of sclerostin has also been demonstrated in the aortas of patients undergoing aortic valve replacement [12] .
As a working hypothesis, we proposed that CKD-induced increase in osteoclastic (OPG) and osteoblastic (sclerostin and DKK1) inhibitors impaired bone and vascular cross-talk leading to vascular calcifications. We therefore investigated in this cross-sectional study of ND-CKD patients the relationships between OPG, sclerostin, DKK1, PTH and coronary artery calcifications (CAC).
M AT E R I A L S A N D M E T H O D S

Ethics statement
The study was conducted according to the principles of the Declaration of Helsinki and in compliance with the International Conference on Harmonization/Good Clinical Practice regulations. According to the French Law, the study has been registered at 'Ministère de la Santé et des Solidarités' after approval by the Montpellier University Hospital's ethics committee (Comité de Protection des Personnes Sud Méditerranée IV) with the following number 2006-A00416-45. All patients gave their written informed consent.
Subjects
Two hundred and forty-one ND-CKD patients at various stages of kidney disease, issued from the outpatient general nephrology consultation of the Montpellier Lapeyronie university hospital, were enrolled in this cross-sectional study. Inclusion criteria were age ≥18 years and presence of CKD defined, in agreement with the National Kidney Foundation [13, 14] , as either kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m 2 for ≥3 months. Kidney damage was defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.
Causes of CKD were glomerulonephritis (n = 32), cystic renal disease (n = 20), diabetic nephropathy (n = 26), diabetic and hypertensive nephropathy (n = 22), angiosclerosis and hypertensive nephropathy (n = 93), infectious/obstructive interstitial nephropathy (n = 5), renal neoplasia (n = 2), genetic/ congenital cause (n = 3), necrotizing angiitis (n = 4), unknown cause (n = 13) and other cause (n = 21).
Detailed medical history including age, gender, weight, height, diabetes mellitus, hypertension, past or current smoking, presence of atherosclerotic cardiovascular disease was recorded.
Existence of hypertension was defined by brachial blood pressure higher or equal to 130/80 mmHg and/or by a current antihypertensive treatment.
Presence of atherosclerotic cardiovascular disease was defined by the presence of at least one of the three following manifestations: coronary heart disease (CHD), cerebrovascular disease (CVD) or peripheral vascular disease (PVD). CHD was defined as documented angina pectoris or history of myocardial infarction. Angina pectoris was described as chest pain arising at exertion and disappearing with nitroglycerine or rest. The diagnosis may also have been made by a positive evaluation in nuclear medicine or a coronary stenosis >75% of luminal diameter evidenced by angiography. Myocardial infarction was defined as clinical symptoms, such as chest pain or dyspnoea, associated with abnormal electrocardiogram and elevated troponins. CVD was defined as previous clinical cerebral disease (transient ischaemic attack or stroke) or the presence of atheromatous plaques on internal carotid arteries. PVD included clinical symptoms such as intermittent claudication, abolished peripheral pulses or diminished arterial pulses or signs of atheromatous involvement of the lower limb diagnosticated by Doppler ultrasound.
Procedures
Laboratory measurements. Blood samples were collected as part of our regular CKD patient follow-up, centrifuged and supernatant was stored at −80°C for processing of creatinine, calcium, phosphate (PO 4 ), 25(OH) vitamin D, 1,25(OH) 2 vitamin D, intact parathyroid hormone (iPTH), high sensitive C-reactive protein (hs-CRP), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), OPG, sclerostin and DKK1. All measurements were sequentially done with less than 1-year intervals after freezing.
Creatinine was measured by IDMS-traceable enzymatic method (Olympus, Rungis, France) [15] using reagents from Randox (Randox, Mauguio, France), and GFR was estimated using the CKD-EPI equation [16] . Use of IDMS-traceable enzymatic creatinine assay and CKD-EPI equation allows estimated glomerular filtration rate (eGFR) determination up to 90 [17] or 120 mL/min/1.73 m 2 [18] . Calcium and PO 4 were assessed by colorimetric method (Olympus). 25(OH) vitamin D and 1,25(OH) 2 vitamin D were measured by radioimmunoassay (Immunodiagnostic Systems, Boldon, UK). iPTH was measured by immunoradiometric assay (N-Tact PTH SP IRMA Kit, DiaSorin, Stillwater, MN; Bi Ins IRMA, Cisbio International, Bagnols-sur-Cèze, France). hs-CRP was determined by immunoturbidimetry (Olympus). bALP was assessed using IDS-iSYS Ostase BAP control kit (Immunodiagnostic Systems, Boldon, UK). OPG, sclerostin and DKK1 were determined by enzyme-linked immunosorbent assay (OPG: Biovendor Laboratory Medicine, Brno, Czech Republic [19, 20] ; Sclerostin: TECOmedical Quidel Corporation, San Diego, CA; DKK1: Biomedica Medizinprodukte GmbH, Wien, Austria).
Coronary artery calcification imaging. All patients underwent multidetector computed tomography (MDCT).
Regarding data acquisition, all MDCT scans derived from a multidetector-row spiral CT (Lightspeed VCT, General Electric Medical System, Milwaukee, WI). Prospective ECGtriggered step-scan was performed using with 2.5-mm collimation width ×64 detectors so that the centre of the temporal window corresponded to 70% of the R-R interval. The scanning parameters were a gantry rotation speed of 0.35 s/rotation, 120 kV and 300 mA 8 × 5 collimation, and 20-mm table feed per rotation. The matrix size was 512 × 512 pixels and the display field of view was 25 cm. The reconstruction kernel was standard. The temporal resolution was 250 ms.
Regarding image evaluation, calcium score was calculated using a semi-automatic software (Smartscore version 3.5, Advantage Window 4.4 workstation, General Electric Medical System). Coronary calcification was defined as a plaque of ≥4 pixels (area = 1.37 mm 2 ) with a density of ≥130 Hounsfield units. Quantitative calcium scores were calculated according to the method described by Agatston et al. [21] . Coronary calcium scoring was performed by either a physician or computed tomography technician with specific training for the methodology described above.
Statistical methods
Characteristics of the population were described by using proportions for categorical variables and median and range for quantitative variables since their distributions were tested with the Shapiro-Wilk statistic and were mostly skewed.
Associations between the extent of CAC divided into two groups (<100 versus ≥100) and patient characteristics, vascular risk biomarkers, biological parameters were quantified with odds ratio (OR) and their 95% confidence intervals (95% CIs). The cut-off used for CAC has been chosen by respect to CAC scoring: those with CAC below 100 (considered as patients with insignificant or mild CAC) and those with CAC equal or above 100 ( presence of moderate to severe CAC) [22, 23] . Biological parameters were divided into tertiles. In the case of OPG and sclerostin, patients were also divided into two categories, those with a low level (<6.26 pmol/L for OPG; <0.748 ng/mL for sclerostin, corresponding to the first tertile) and those with a high level (≥6.26 pmol/L for OPG; ≥0.748 ng/mL for sclerostin, corresponding to the second and third tertiles).
When appropriate, the interaction terms were tested using Wald χ 2 test given by the logistic regression model. In order to determine whether OPG and sclerostin were independently associated with CAC, the two biomarkers were entered together in the same logistic regression model with potential confounders associated with a P < 0.10. Finally, to study the potential additive effects of OPG and sclerostin on the presence of CAC, a composite index has been created to merge patients with high level of OPG and high level of sclerostin. This index was adjusted for clinical and socio-demographic variables associated with the presence of CAC (with P < 0.15).
To analyse the relationships between CAC and both OPG and sclerostin, the fractional polynomial method was used [24] . This method consists of expressing the exposure variable as a continuous variable, with CAC replacing the simple linear function of this variable in the model by a more general flexible function. For example, the simple linear function of OPG was compared with a quadratic function ( polynomial fractional of order two). The Royston model-selection algorithm was then used to check whether the linear function was adequate or whether the non-linear fractional polynomial function improved the fit of the data [25] .
Partial correlation networks were done to represent crosssectional interconnections between the different biomarkers on the whole population. A partial correlation is the correlation of two variables while controlling for a third or more covariates. Partial spearman correlations were computed using the ppcor package for R software. Significant correlations at the P = 0.05 threshold were represented on correlation plots. Since the analysis was considered as exploratory, no adjustment for multiple tests was performed.
Significance was set at P < 0.05. All analyses were carried out with SAS software, version 9.3 (SAS Institute, Cary, NC), STATA software, version 11 (STATA Corp.) and the program R 3.1.0 (The R Project for statistical computing, www.r-project. org).
R E S U LT S
Clinical and biological characteristics for the patients Clinical and biological characteristics for the patients are summarized in Table 1 . Table 2 reports the crude associations between sociodemographic, clinical and biological characteristics according to OPG (in tertiles of the population) and sclerostin (in tertiles of the population) levels. High OPG levels were associated with increased age, a history of CHD, decreased levels of eGFR, calcium and 1,25(OH) 2 vitamin D and increased levels of hs-CRP, PTH, sclerostin, bALP and CAC (P < 0.05 for all these comparisons). High sclerostin levels were associated with male gender, increased age and BMI, diabetes, hypertension, an history of CHD, decreased levels of eGFR, HDL cholesterol and 1,25 (OH) 2 vitamin D, increased levels of OPG and CAC (P < 0.05 for all these comparisons).
No significant association between either OPG or sclerostin and smoking habits, lipid parameters (triglycerides and LDL cholesterol), bicarbonates, phosphate, 25(OH) vitamin D or DKK1 was observed.
Relationships between CKD stages and bone and mineral metabolism markers Decline in renal function was associated with a significant increase in PO 4 , iPTH, bALP, OPG and sclerostin while a slight but significant decrease in DKK1 was observed (Table 3) . Two-third of the patients presented (i) iPTH levels below or within the normal range defined by the laboratory (reference range: 11-62 pg/mL) and (ii) bALP below the mean value defined by the laboratory (mean laboratory bALP: 11.8 ± 6.0 µg/L).
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Relationships between coronary artery calcifications and bone and mineral metabolism markers Characteristics of the patients according to the level of CAC. Among the 241 patients studied, 100 (41.5%) had insignificant or mild CAC (score <100), and 141 (58.5%) patients had moderate to severe CAC (score ≥100). Table 4 shows the association between clinical markers and the presence of CAC. Presence of CAC (score ≥100) was significantly associated with age (P < 0.0001), male gender (P < 0.0001), diabetes (P < 0.0001), body mass index (BMI) (P = 0.02) and smoking habits (P = 0.0012). No significant relationship between therapeutic interventions and presence of CAC was reported.
Relationships between biological markers of vascular risk and the extent of CAC. Figure 1 depicts the relationships between CAC and both OPG and sclerostin. Two models were shown: the model with a polynomial of order 2 (the form of the model was β 0 + β 1 x p + β 2 x q ) and the linear model. The latter was represented as a 'referent' model. Using the Royston selection algorithm, we showed that the linear model fits the data better than the non-linear risk model for the relationship between OPG and CAC: the deviance of the best second-degree fractional polynomial model was equal to 301.209 and the deviance of the linear model was equal to 304.147; the comparison of the deviance difference with a χ 2 on 3 degrees of freedom was P = 0.401.
With the same methodology, we reported that the linear model fits the data better than non-linear risk models for the relationship between sclerostin and CAC; the deviance of the best second-degree fractional polynomial model being equal to 302.99 and the deviance of the linear model being equal to 308.423. The comparison of the deviance difference with a χ 2 on 3 degrees of freedom was P = 0.143.
OPG and sclerostin are independently associated with CAC. In order to identify whether OPG and sclerostin were independently associated with CAC, the two biomarkers were introduced into a multivariate model adjusted for potential confounders (Table 6 ). These two biomarkers were independently associated with CAC in crude associations (Table 6 The nature of vascular calcifications being different in diabetic patients, interactions between diabetes and (i) OPG and (ii) sclerostin for the risk of CAC were tested but were not significant (P = 0.59 and P = 0.34, respectively). OPG and sclerostin as partners of mineral metabolism markers. In order to speculate on the potential relationships between the different biomarkers studied, Spearman partial 
correlation that measures the degree of association between two random variables after excluding the effect of all covariates was graphically represented on Figure 3 . Significant partial correlations between OPG, sclerostin, eGFR and CAC were represented in Panel A. This initial correlation network was then augmented with all bone mineral metabolism markers (Panel B). When only considering eGFR, CAC, OPG and sclerostin, it could be evidenced that decline in renal function is clearly associated with increased OPG (ρ = −0.42; P < 0.0001) and sclerostin (ρ = −0.36; P < 0.0001) which are in turn related to coronary calcifications (ρ = 0.29; P < 0.0001 for OPG and ρ = 0.22; P = 0.0005 for sclerostin). In contrast, no direct relationship could be evidenced between eGFR and CAC. Taking into account the potential mineral metabolism markers, OPG was positively correlated to (i) sclerostin (ρ = 0.13; P = 0.0389), (ii) bALP (ρ = 0.22; P = 0.0008) and negatively correlated to iPTH (ρ = −0.13; P = 0.0388). PTH was also positively associated with bALP (ρ = 0.28; P < 0.0001) and negatively correlated with DKK1 (ρ = −0.23; P = 0.0003). A negative correlation between sclerostin and (i) bALP (ρ = −0.23; P = 0.0004) and (ii) 1,25(OH) 2 vitamin D (ρ = −0.21; P = 0.0014) was also observed. No significant correlation was found between sclerostin and iPTH or other biochemical parameters.
It is also to note that vitamin D supplement use or eGFR did not modify the relationships between sclerostin and iPTH.
D I S C U S S I O N
In the present study, we analysed the relationships between bone turnover inhibitors, OPG, sclerostin and DKK1 and CAC in a population of 241 ND-CKD patients. We firstly confirmed the significant increase in OPG and sclerostin levels along with the decline in GFR. Both bone turnover inhibitors are strongly and independently associated with CAC. And more importantly, our study showed for the first time the potential additive effects of their association to CAC, in patients without any biological signs of low or high bone turnover determined by PTH or bALP [26] . In contrast, DKK1 level decreased with the progression of kidney dysfunction and was not associated with CAC. The increase in OPG and sclerostin levels with the progression of kidney failure has been well described by several studies. 
O R I G I N A L A R T I C L E
P r e d i c t i v e v a l u e o f O P G / s c l e r o s t i n o n C A C i n N D -C K D
As previously reported on OPG [27] , we observed a strong and inverse relationship between sclerostin and renal function. Our results are in total agreement with Pelletier et al.'s study [28] showing that, in ND-CKD patients, sclerostin levels increase with GFR decline; GFR, sex and serum phosphate being the only determinants of sclerostin levels. More recently, Cejka et al. demonstrated that such accumulation of serum sclerostin with declining kidney function was not related to any renal retention but rather was the consequence of an increased production by osteocytes [29] , whose mechanisms are still unknown. It has been suggested that sclerostin levels could be related to PTH in CKD [30] , in diabetes [31] or in primary hyperparathyroidism [32] . However, as previously reported by Pelletier [28] and Thambiah [33] , we did not observe any significant correlation between PTH and sclerostin (Figure 3) . In our population, this effect may be masked by the low levels of PTH observed either in a context of early stages of CKD or oversuppression by vitamin D for advanced stages. PTH-independent mechanisms for sclerostin regulation could be another explanation.
DKK1 has an opposite pattern in our population of ND-CKD patients since DKK1 levels decrease according to CKD stages and are negatively correlated with PTH. Here again, contradictory results are reported in the literature. Kulkarni et al. reported a down-regulation of mRNA level for DKK1 in response to PTH treatment both in vitro in cultured UMR106 cells and in a murine model [34] . In contrast, osteoporosis or primary hyperparathyroidism could rather evidence positive correlations between PTH and DKK1 [32, 35, 36] . Finally, in Stage 5 CKD patients on dialysis, Cejka et al. could not even show any significant association between DKK1 and PTH [30] . To our knowledge, we reported for the first time a slight but significant decrease in DKK1 level with GFR decline. Indeed, Thambiah et al. [33] only studied Stages 3B and 4 CKD patients and could not report any significant difference in DKK1 levels between these two stages, the decrease in DKK1 occurring earlier, from Stage 3 CKD. Finally, the opposite patterns of DKK1 and sclerostin (decreased DKK1 but increased sclerostin levels) with GFR decline along with their discrepant association seen with PTH suggest that these two bone formation inhibitors do not share common regulatory pathways in ND-CKD patients.
Previous studies have reported an association between high OPG levels and CAC in CKD (in particular two from our group) [7, 27] and haemodialysis (HD) [8, 37, 38] patients. Predictive value of the Wnt signalling pathway inhibitors for VC has also been reported but with opposite associations. High sclerostin concentrations were reported to be associated with aortic calcifications, abnormal intima-media thickness and carotid plaques in type 2 diabetes males [11] . Hampson et al. also observed same positive associations with abdominal aortic calcifications in post-menopausal women [10] . Conversely, in CKD patients, relationships between sclerostin and VC appear more controversial. Claes et al. [39] found higher sclerostin levels in ND-CKD patients with aortic calcifications. But, surprisingly, in multivariate analysis the association became inverse. In HD patients, high serum sclerostin was associated with the extent of aortic valve calcification and also co-localized with areas of calcification in aortic valve tissue [40] . However, the same authors could not evidence any positive relationships with CAC, as we report in the present study in pre-dialysis patients. It is noteworthy Second-degree fractional polynomial model (full line); linear model (short dashes). The vertical axis is scaled as the logit of the probability (P) of presence of CAC ½logit P ¼ lnðPÞ=ð1 À PÞ . that they only included 65 subjects (and already on dialysis) which might explain the discrepant associations observed. Importantly, our results showing a positive association between CAC and sclerostin are in line with the findings of Kanbay et al. [41] who found in CKD stage 3-5 patients high sclerostin value as a predictive marker of fatal and non-fatal cardiovascular events. Similarly, their population of CKD patients had relatively low iPTH and no correlation between iPTH and sclerostin was also observed. Few studies investigated the relationships between DKK1 and VC. One study reported negative relationships between DKK1 and atherosclerotic calcified plaques in African-Americans with type 2 diabetes [42] . The same trend was observed between DKK1 and abdominal aortic calcifications in post-menopausal women [10] . In contrast, only one report from Kim et al. was in line with our data showing positive correlates with CAC and atherosclerotic plaques in patients admitted to the hospital complaining of chest pain [43] . The she different associations observed here between anti-anabolic factors (sclerostin and DKK1) and CAC may be explained by the fact that they are differentially regulated by bone cells in CKD, sclerostin being mainly expressed by osteocytes while DKK1 being expressed by osteocytes and osteoblasts.
Finally, one original finding of the present work was the independent and potentially additive effect of bone turnover inhibitors (both OPG and sclerostin) in their association with CAC, in a context of low to normal PTH levels. The slight additive effect of the two markers on CAC suggests that both anti-anabolic and anti-catabolic bone factors may conspire to increase the risk for VC despite an overlapping biological effect. This hypothesis is further supported by the Spearman partial correlation depicted in Figure 3 . Panel A clearly illustrates the involvement of renal function impairment in the increase in OPG and sclerostin which in turn results in vascular calcifications. Panel B further demonstrates that, among all biomarkers studied, only high OPG and high sclerostin levels are associated with the presence of CAC. Prevention of vascular calcifications may therefore be possible through the modulation of one or both of the two inhibitors.
A direct or indirect influence of PTH on these modulations may be speculated. Indeed, as previously discussed, OPG and sclerostin increase during the course of CKD potentially resulting in low bone turnover. However, simultaneously, PTH levels increase in a context of secondary hyperparathyroidism. This increase could counterbalance the effect of OPG by increasing RANKL level (see also on Figure 3 the negative weak correlation between PTH and OPG) and could directly [30] or indirectly down-regulate the expression of sclerostin (through the action of 1,25(OH) 2 vitamin D, see in Figure 3 the negative correlation between 1,25(OH) 2 vitamin D and sclerostin) leading to a new equilibrium. Thus, we speculate that PTH in higher levels would probably maintain a potential steady state between bone turnover inhibitors and PTH with a beneficial effect on the vasculature. Optimal PTH, OPG and sclerostin levels should therefore be defined in ND-CKD patients in order to prevent calcifications of the vessels but difficulties still occur due to (i) differences in kinetics of production of these proteins, (ii) medication that influences their levels and finally, (iii) the occurrence of a PTH resistance in advanced CKD stage [44] .
Our study acknowledged some limitations. The cross-sectional nature of this study cannot clearly evidence any causality between bone turnover inhibitors and (i) PTH and (ii) CAC, a prospective study being strongly required. This is a single-centre study which may potentially limit external validity.
Regarding biological parameters (i) data on soluble RANKL which would have been of any help in the explanation of underlying mechanisms are missing (ii) sclerostin ELISA kit is not a standardized assay [28] .
In conclusion, changes in mineral metabolism as well as interactive cross-talk between vascular and skeletal systems play a crucial role in the development of VC. It is quite difficult to regulate PTH and control calcium and phosphorus levels to normalize bone mineral metabolism but its regulation as well as equilibration with bone turnover inhibitors appear essential to prevent their accumulation and the subsequent increased risk of VC. Whether their inhibition (with use of antisclerostin antibody for example) will protect from VC and/ F I G U R E 2 : Prevalence rate ratio of coronary artery calcifications associated with increased levels of osteoprotegerin and/or sclerostin levels. 
S U M M A RY
The present study demonstrates in a cross-sectional study that bone turnover inhibitors, OPG and sclerostin, are independently associated to CAC with potential additive effects in ND-CKD patients. The risk to present CAC was significantly increased when both OPG and sclerostin levels were high [crude model: OR = 11.47 (4.54-29.0); P < 0.0001; model adjusted for age, gender, diabetes, body mass index and smoking habits: OR = 5.69 (1.76 -18.4); P = 0.02].
AC K N OW L E D G E M E N T S
The authors acknowledge the nurses from Policlinique at Lapeyronie Hospital especially Anne Bebengut and Hélène Lebihan for patient appointment scheduling and blood withdrawals. This work was partly supported by a grant from Ministère de la Santé (PHRC-UF 7853).
CO N F L I C T O F I N T E R E S T S TAT E M E N T
BC is a full-time employee of Fresenius Medical Care.
The results presented in this paper have not been published previously in whole or part, except in abstract format. 
